

Dipyrone, HRP conjugate

DAG1094

Lot. No. (See product label)

PRODUCT INFORMATION

Product overview	Dipyrone, HRP conjugate
Antigen Description	Dipyrone or "Mexican aspirin" is a nonsteroidal anti-inflammatory drug. The mechanism of action of dipyrone is thought to be similar to that of other NSAIDs: inhibition of the production of prostaglandins. Dipyrone is not approved for use in many countries (including USA, UK) because of fears about agranulocytosis, though this is controversial. However sales of the drug continue in Mexico and other developing countries.
Source	Anti-Inflammatory Drugs
Conjugate	HRP
Form	concentrate
Characteristic	Each conjugate comprises antigen covalently bound to horseradish peroxide and is suitable as a tracer in immunoassay development

PACKAGING

Storage	Can be stored at 2-8°C for up to 3 months and at -20°C for longer term storage.
----------------	---

BACKGROUND

Introduction	Metamizole sodium or dipyrone is a powerful analgesic and antipyretic. It is marketed under various trade names, including Algozone, Algocalmin, Analgin, Dipirone, Novalgin, Neo-Melubrina and Optalgin. Metamizole was first synthesized by the German company Hoechst AG (now part of Sanofi) in 1920, and its mass production started in 1922. It remained available worldwide until the 1970s, when it was discovered that the drug carries a small risk of causing agranulocytosis - a potentially fatal condition. Controversy remains regarding the level of risk. Several national medical authorities have banned metamizole either totally or have restricted it to be available only on prescription, while others have maintained its availability over the counter.
Keywords	Metamizole sodium; dipyrone; Sodium [(2,3-dihydro- 1,5-dimethyl- 3-oxo- 2-phenyl- 1H- pyrazol- 4-yl) methylamino] methanesulfonate; LABOTEST-BB LT00134649; SULPYRINE MONOHYDRATE; ANALGINE, PHARMA; Analgin; Novalgin

REFERENCES

1. Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998; 51: 1357-1365.
2. The Pharmaceutical Industry — Prices and Progress. F.M. Scherer, Ph.D. N Engl J Med 2004; 351:927-932 August 26, 2004.